Stockreport

Pyxis Oncology's Cancer Drug Platform Shows Potential, Analyst Sees Over 190% Upside [Yahoo! Finance]

Pyxis Oncology, Inc.  (PYXS) 
PDF antibody-drug conjugates (ADCs) with enhanced potency, stability, and tolerability. The analyst points out that Pyxis' lead drug, PYX-201, is an ADC that targets Extra [Read more]